RxDoctor Payments DataLook up a doctor →

Michelle Bassett

Nurse Practitioner · Washington, MONPI 1124688858

Payments from drug & device makers

$8,079in general payments, 2019–2025

Across 469 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$670
  • AstraZeneca$610
  • GSK$500
  • Otsuka America Pharmaceutical, Inc.$469
  • Novartis$431
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$8,079100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,079 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$13,884
Medicare patients
68
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol133$94,856
OzempicSemaglutide68$73,799
MounjaroTirzepatide70$72,798
JardianceEmpagliflozin65$54,184
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$29,795
TrulicityDulaglutide27$28,995
JanuviaSitagliptin Phosphate24$23,210
EliquisApixaban37$23,050
Nurtec OdtRimegepant Sulfate11$22,047
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$17,162
Xigduo XrDapaglifloz Propaned/Metformin15$11,597
Repatha SureclickEvolocumab16$9,995
TradjentaLinagliptin11$6,962
Janumet XrSitagliptin Phos/Metformin Hcl13$5,816
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$5,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$610$112,017155 claims
Lilly USA, LLCMounjaro, Trulicity$670$101,79397 claims
Novo NordiskOzempic$426$73,79968 claims
Boehringer IngelheimJardiance, Tradjenta$16$61,14676 claims
PfizerEliquis, Nurtec Odt$65$45,09748 claims
MerckJanuvia, Janumet Xr, Janumet$84$30,93548 claims
GSKTrelegy Ellipta$500$29,79537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →